Skip to content

NPWTi on Closure of Chronic Pressure Sores

Evaluation of Vacuum-Assisted Closure Veraflo Therapy With Cleanse Choice Dressing on Wound Healing in Patients With Pressure Sores: A Prospective, Randomized Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05598398
Enrollment
62
Registered
2022-10-28
Start date
2022-09-26
Completion date
2027-05-01
Last updated
2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pressure Sore

Brief summary

The primary objective of this study is to assess the effectiveness of the Negative Pressure Wound Therapy system with instillation therapy (NPWTi) on closure of chronic pressure sores. This intervention will be compared to wet-to-dry dressings, which is standard of care. In this post-market, on-label study, we hope to show that the NPWTi system more effectively closes pressure sores following debridement than traditional care.

Interventions

The V.A.C.Ulta™ Negative Pressure Wound Therapy System is a 510(k) - cleared, Class II device (K100657) with the following indication for use: "the V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option.

OTHERStandard of Care (Wet-to-dry dressings)

Wet-to-dry dressings

Sponsors

Northwestern University
Lead SponsorOTHER
3M
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Ischial and sacral wounds at stage 3 and 4. 2. Any pressure sore that has the potential for a good seal.

Exclusion criteria

1. Any pressure sore that does not have potential for a good seal. 2. Patients with fecal incontinence (due to potential for pressure sore to be near the anus). 3. Patients who by the opinion of the Principal Investigator are not candidates for surgical closure (age, BMI, comorbidities, etc.). 4. Patients who are pregnant. This is standard of care for surgery anyway, and there is uncertainty of how both the surgery and intervention would affect the fetus. We therefore stress any form of birth control, abstinence, and method to prevent pregnancy for those enrolled in the study.

Design outcomes

Primary

MeasureTime frameDescription
Total Length of Stayup to 3 monthsRecord the number of days spent in the hospital from initial debridement (first visit with plastic surgeon) to discharge from hospital following surgery

Secondary

MeasureTime frameDescription
Cost AnalysisThrough study completion, approximately 5 monthsTotal costs of dressings, hospital stay, direct patient care and other costs involved in inpatient care.
Number of debridementsThrough study completion, approximately 5 monthsRecord the total number of debridements performed at the wound site throughout the duration of the study
Successful closure of pressure sores2 weeks and 6 weeks post-closure surgeryPatients will be assessed for proper closure of the wound

Countries

United States

Contacts

CONTACTRobert Galiano, MD
robert.galiano@nm.org3129267037
CONTACTKristin Huffman, B.S.
kristin.huffman@northwestern.edu3129267037
PRINCIPAL_INVESTIGATORRobert Galiano, MD

Northwestern University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026